Noxopharm

24 articles about Noxopharm

• FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

  3/29/2022

  Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda ® , its lead oncology drug candidate , for use in the treatment of soft tissue sarcoma.

• Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

  3/8/2022

  Australian clinical-stage drug development company Noxopharm has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California.

• Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

  12/1/2021

  Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research,

• 

  Clinical Catch-Up: November 8-12

  11/15/2021

  It was another busy week for clinical trial news. Here’s a look.

• Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

  8/26/2021

  Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda® , as an anti-inflammatory drug for early-stage COVID-19 treatments.

• Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

  8/12/2021

  Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

• Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing

  5/11/2021

  Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) today announced its CEP-2 study will begin shortly. CEP-2 is related to the Investigational New Drug (IND) approval of Veyonda ® by the FDA based on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy

• Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

  4/27/2021

  Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.

• Noxopharm Files Septic Shock Treatment Patent for Veyonda®

  4/14/2021

  Noxopharm Files Septic Shock Treatment Patent for Veyonda ® New indication doubles the commercial opportunity

• Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

  11/12/2020

  Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda ® , to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo ® ) in the treatment of cancer. Veyonda is a first-in-class sphingosine-1-phosphate inhibitor with h

• Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

  10/8/2020

  As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda ® , in the Company’s Phase 1 NOXCOVID-1 study. NOXCOVID-1 is looking at treating those COVID-19 patients hospitalize

• Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’

  7/23/2020

  Noxopharm , a clinical-stage Australian oncology drug development company listed on the ASX (ASX:NOX), has claimed a breakthrough in the search for restoring immune function within “cold” microtumors, converting them to so-called “hot” tumors. The breakthrough stems from new preclinical data from two independent research groups. The data confirms that idronoxil, the active ingredient in the company’s immuno-oncology drug ca

• Noxopharm Reports COVID-19 Trial Program to Commence in Europe

  6/25/2020

  Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.

• Noxopharm Reports Veyonda’s Potential in Late-Stage Cancer at ASCO 2020

  6/4/2020

  At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm , a clinical-stage Australian oncology drug development company, has reported two sets of clinical data relating to the development of NOX66 ( Veyonda ® ) as a treatment for end-stage cancer. The posters addressed how NOX66 may improve treatment responses in men with mCRPC and also its contribution to restoring sensitivity to apop

• Noxopharm Achieves Abscopal Responses in Prostate Cancer

  5/6/2020

  Noxopharm , a clinical-stage Australian oncology drug development company, has announced the details of the radiographic review of its DARRT-1 clinical study and is pleased to report a 27% incidence of abscopal response in soft tissue lesions using a combination of Veyonda® and low-dose radiotherapy. An abscopal response, a highly prized clinical response, involves radiation directed at a single tumor which triggers resulting

• Noxopharm Investigating Potential COVID-19 Treatment

  4/2/2020

  Noxopharm, a clinical-stage Australian oncology drug development company, has identified a clinical trial opportunity that could help reduce the mortality rate of COVID-19.

• 

  Biopharma Update on the Novel Coronavirus: April 2

  4/2/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.

• FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®

  2/25/2020

  Feb. 25, 2020 13:30 UTC FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda ® Current IND for sarcoma paves the way for future INDs for late-stage prostate cancer SYDNEY--( BUSINESS WIRE )-- Noxopharm (ASX: NOX) announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda ® for combination treatment with doxorubicin in patients with soft tissue sarcomas. “Based on preclinical an

• Positive DARRT-1 Data in Late-Stage Prostate Cancer

  12/2/2019

  Noxopharm (ASX: NOX), an Australian drug development company, reports positive end-of-study data from its DARRT-1 Phase 1b trial.

• Noxopharm Announces Appointment of Chief Commercial Officer

  11/6/2019

  Noxopharm is pleased to announce that it has appointed Mr Alexander Hunter as its Chief Commercial Officer.